来氟米特联合糖皮质激素治疗IgA肾病随机对照临床研究
发布时间:2019-04-03 18:39
【摘要】:背景与目的 IgA肾病是世界范围内最常见的原发性肾小球疾病,约有15% 40%的患者在15年进展至终末期肾脏疾病(ESRD)。其发病机制复杂,临床表现多样,目前尚无治疗IgA肾病的公认方案,免疫抑制剂的应用仍具争议。来氟米特是一种新型免疫抑制剂,近年来被报道用于IgA肾病的治疗,,但关于其疗效评价不一。本研究观察来氟米特联合糖皮质激素治疗IgA肾病的疗效及安全性,从而为临床用药提供参考。 方法 选取2012年8月—2013年2月于郑州大学第二附属医院行肾穿刺活检确诊为IgA肾病的患者60例,年龄在18 50岁之间,24小时尿蛋白定量≥3.5g/d,治疗前血肌酐<265umol/L,Lee分级Ⅱ-Ⅴ级。60例患者随机分为两组——来氟米特联合糖皮质激素组(LEF组)和对照组,每组各30例。LEF组口服醋酸泼尼松片及来氟米特片,醋酸泼尼松片起始剂量为1mg/(kg.d),于8-12周开始减量,每2周减5mg,减至10mg/d时维持3个月渐停药,来氟米特片用量为20mg/d;对照组仅口服醋酸泼尼松片,用法用量同LEF组。所有患者均接受ACEI/ARB药物治疗。治疗时间为12个月。分别于治疗前及治疗后1、3、6、12个月时测定两组24小时尿蛋白定量、血浆白蛋白、血肌酐、肾小球滤过率、胆固醇、甘油三酯、胱抑素C水平,并比较两组疗效及不良反应发生情况。 结果 治疗12个月后LEF组总有效率显著高于对照组(93.3%vs70.0%,P<0.05),但两组完全缓解率无显著差异(33.3%vs20.0%,P>0.05);治疗3个月时LEF组24小时尿蛋白定量较治疗前显著减少(P<0.05),血浆白蛋白较治疗前显著增加(P<0.05),但对照组24小时尿蛋白定量及血浆白蛋白与治疗前比较无显著差异(P>0.05);治疗6个月及12个月时,两组24小时尿蛋白定量均较治疗前显著下降(P<0.05),血浆白蛋白均较治疗前显著增加(P<0.05)。治疗12个月时LEF组24小时尿蛋白定量较对照组显著下降(P<0.01),血浆白蛋白较对照组显著增加(P<0.01);整个治疗过程中两组的血肌酐、肾小球滤过率、胆固醇、甘油三酯、胱抑素C的变化无显著差异(P>0.05)。LEF组完全缓解患者未见复发,对照组有4例患者病情复发,两组复发率有显著差异(0%vs13.3%,P<0.05)。LEF组及对照组的不良反应发生率分别为10.0%和7.1%,两组无统计学差异(P>0.05),未发生严重不良反应。 结论 来氟米特联合糖皮质激素治疗IgA肾病与单用糖皮质激素相比能更有效降低尿蛋白,升高血浆白蛋白,降低复发率。
[Abstract]:Background & objective IgA nephropathy is the most common primary glomerular disease in the world. About 15% to 40% of patients progress to end-stage renal disease (ESRD). In 15 years. The pathogenesis of IgA nephropathy is complicated and its clinical manifestations are diverse. At present, there is no accepted scheme for the treatment of HBV nephropathy, and the application of immunosuppressive agents is still controversial. Leflunomide, a new immunosuppressive agent, has been reported for the treatment of IgA nephropathy in recent years. In this study, we observed the efficacy and safety of leflunomide combined with glucocorticoid in the treatment of IgA nephropathy. Methods from August 2012 to February 2013, 60 patients with IgA nephropathy were diagnosed by renal biopsy in the second affiliated Hospital of Zhengzhou University. The age was between 18 years old and 50 years old, and the 24-hour urinary protein quantity was 鈮
本文编号:2453459
[Abstract]:Background & objective IgA nephropathy is the most common primary glomerular disease in the world. About 15% to 40% of patients progress to end-stage renal disease (ESRD). In 15 years. The pathogenesis of IgA nephropathy is complicated and its clinical manifestations are diverse. At present, there is no accepted scheme for the treatment of HBV nephropathy, and the application of immunosuppressive agents is still controversial. Leflunomide, a new immunosuppressive agent, has been reported for the treatment of IgA nephropathy in recent years. In this study, we observed the efficacy and safety of leflunomide combined with glucocorticoid in the treatment of IgA nephropathy. Methods from August 2012 to February 2013, 60 patients with IgA nephropathy were diagnosed by renal biopsy in the second affiliated Hospital of Zhengzhou University. The age was between 18 years old and 50 years old, and the 24-hour urinary protein quantity was 鈮
本文编号:2453459
本文链接:https://www.wllwen.com/yixuelunwen/mjlw/2453459.html
最近更新
教材专著